Viking Therapeutics Files Q1 2025 10-Q
Ticker: VKTX · Form: 10-Q · Filed: Apr 24, 2025 · CIK: 1607678
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, reporting
TL;DR
Viking Therapeutics Q1 2025 10-Q filed. Financials and operations update.
AI Summary
Viking Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, including details on its equity incentive plans and stock repurchase programs. Key financial data and operational highlights from the first quarter of 2025 are presented.
Why It Matters
This filing provides investors with an update on Viking Therapeutics' financial health and operational progress during the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Viking Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial and operational data)
- 2025-03-31 — Period End Date (Specific date for financial reporting)
- 2025-02-27 — Repurchase Program Date (Date related to the company's repurchase program)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250424 (date) — Filing date
- 9920 PACIFIC HEIGHTS BLVD, SUITE 350 (address) — Company's business and mailing address
- SAN DIEGO, CA 92121 (address) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on April 24, 2025.
What is Viking Therapeutics, Inc.'s primary business sector?
Viking Therapeutics, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
What is the company's business address?
The company's business address is 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121.
Are there any specific dates mentioned related to stock repurchase programs?
Yes, February 27, 2025, is mentioned in relation to a repurchase program.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 24, 2025 regarding Viking Therapeutics, Inc. (VKTX).